肝癌介入治疗新进展

摘要/Abstract

摘要： 肝癌是最常见的恶性肿瘤之一,介入治疗已经成为肝癌重要的治疗手段。肝癌介入治疗已经从最初针对中期肝癌的单纯肝动脉化疗栓塞（transcatheter arterial chemoembolization ,TACE）治疗发展到贯穿不同分期肝癌的多种介入治疗方法。特别是随着近年来介入治疗设备、器材、材料的快速发展,肝癌介入治疗的发展日新月异。本文就TACE、肝动脉放射栓塞、肝癌经皮消融治疗（射频消融、微波消融、冷冻消融、不可逆电穿孔）、放射性粒子近距离治疗、介入治疗联合分子靶向和免疫治疗等方面的最新进展展开述评,并对肝癌介入治疗相关的新药物、新材料、新设备进行展望。

关键词: 肝癌, 介入治疗, 应用进展

Abstract: As one of the most common malignant tumors, interventional therapy has become an important treatment for liver cancer. The interventional therapy of liver cancer has developed from TACE (transcatheter arterial chemoembolization) to a variety of interventional therapy through different stages of liver cancer. Especially with the rapid development of interventional therapy equipment, and materials in recent years, the development of interventional therapy for liver cancer is changing rapidly. This paper reviews the latest progress in TACE, transcutaneous ablation of liver cancer (radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation), brachytherapy with radioactive particles, interventional therapy combined with molecular targeting and immunotherapy, and looks forward to new drugs, materials and equipment related to interventional therapy of liver cancer.

Key words: Liver cancer, Interventional therapy, Application progress

徐克, 邵海波. 肝癌介入治疗新进展[J]. 肝癌电子杂志, 2020, 7(3): 2-6.

Xu Ke, Shao Haibo. New progress of interventional therapy for liver cancer[J]. Electronic Journal of Liver Tumor, 2020, 7(3): 2-6.

参考文献

[1] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J] . 肿瘤综合治疗电子杂志, 2020, 6(2):55-85.
[2] TSURUSALI M, MURALAMI T.Surgical and Locoregional Therapy of HCC:TACE[J] . Liver Cancer, 2015, 4(3):165-175.
[3] GOLFIERI R, GIAMPALMA E, RENZULLI M, et al.Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma[J] . Br J Cancer, 2014, 111(2):255-264.
[4] SACCO R, BARGELLINI I, BERTINI M, et al.Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma[J] . J Vasc Interv Radiol, 2011, 22(11):1545-1552.
[5] ANGELICO M.TACE vs DEB-TACE:Who wins?[J] Dig Liver Dis, 2016, 48(7):796-797.
[6] SALEM R, LEWANDOWSKI R, ROBERTS C, et al.Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis[J] . J Vasc Interv Radiol, 2004, 15(4):335-345.
[7] SPREAFICO C, SPOSITO C, VAIANI M, et al.Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion[J]. J Hepatol, 2018, 68(4):724-732.
[8] BIDERMAN DM, TITANO JJ, KORFF RA, et al.Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma[J]. J Vasc Interv Radiol, 2018, 29(1).
[9] VOUCHE M, LEWANDOWSKI RJ, TASSI R, et al.Radiation lobectomy:time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection[J]. J Hepatol, 2013, 59(5):1029-1036.
[10] SALEM R, GORDON AC, MOULI S, et al.Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma[J]. Gastroenterology, 2016, 151(6).
[11] SALEM R, GABR A, RIAZ A, et al.Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience[J]. Hepatology, 2018, 68(4):1429-1440.
[12] KULIK L, VOUCHE M, KOPPE S, et al.Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma[J]. J Hepatol, 2014, 61(2):309-317.
[13] NAULT JC, SUTTER O, NAHON P, et al.Percutaneous treatment of hepatocellular carcinoma:State of the art and innovations[J]. J Hepatol. 2018, 68(4):783-797.
[14] HOCQUELET A, AUBE C, RODE A, et al.Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC[J]. J Hepatol, 2017, 66(1):67-74.
[15] HUANG J, YAN L, CHENG Z, et al.A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria[J]. Ann Surg, 2010, 252(6):903-912.
[16] CUCCHETTI A, PISCAGLIA F, CESCON M, et al.Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma[J]. J Hepatol, 2013, 59(2):300-307.
[17] CHO YK, KIM JK, KIM WT, CHUNG JW.Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma:a Markov model analysis[J]. Hepatology (Baltimore, Md). 2010, 51(4):1284-1290.
[18] LEE Y-H, HSU C-Y, CHU C-W, et al.Radiofrequency ablation is better than surgical resection in patients with hepatocellular carcinoma within the Milan criteria and preserved liver function:a retrospective study using propensity score analyses[J]. J Clin Gastroenterol, 2015, 49(3):242-249.
[19] GLASSBERG MB, GHOSH S, CLYMER JW, et al.Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases:a systematic review and meta-analysis[J]. Onco Targets Ther, 2019, 12:6407-6438.
[20] YI Y, ZHANG Y, WEI Q, et al.Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone[J]. Chinese journal of cancer research, 2014, 26(1):112-118.
[21] NI JY, SUN HL, CHEN YT, et al.Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(46):17483-17490.
[22] ZHANH NN, LU W, CHENG XJ, et al.High-powered microwave ablation of larger hepatocellular carcinoma: evaluation of recurrence rate and factors related to recurrence[J].Clin Radiol, 2015, 70(11):1237-1243.
[23] LIU Y, ZHENG Y, LI S, et al.Percutaneous microwave ablation of larger hepatocellular carcinoma[J]. Clin Radiol, 2013, 68(1):21-26.
[24] LU Z, WEN F, GUO Q, et al.Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials[J]. Eur J Gastroenterol Hepatol, 2013, 25(2):187-194.
[25] VELTRI A, MORETTO P, DORIGUZZI A, et al.Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC)[J]. Eur Radiol, 2006, 16(3):661-669.
[26] Hoffmann NE, Bischof JC.The cryobiology of cryosurgical injury[J]. Urology, 2002, 60(2 Suppl 1):40-49.
[27] WANG C, WANG H, YANG W, et al.Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma[J]. Hepatology (Baltimore, Md), 2015, 61(5):1579-1590.
[28] CHENG RG, BHATTACHARYA R, YEH MM, et al.Irreversible Electroporation Can Effectively Ablate Hepatocellular Carcinoma to Complete Pathologic Necrosis[J].J Vasc Interv Radiol, 2015, 26(8):1184-1188.
[29] SONG Z, YE J, WANG Y, LI Y, WANG W.Computed tomography-guided iodine-125 brachytherapy for unresectable hepatocellular carcinoma[J].J Cancer Res Ther, 2019, 15(7):1553-1560.
[30] ZHU ZX, WANG XX, YUAN KF, et al.Transarterial chemoembolization plus iodine-125 implantation for hepatocellular carcinoma: a systematic review and meta-analysis[J]. HPB (Oxford), 2018, 20(9):795-802.
[31] 蒋璇, 高广毅, 王伟, 等. 复方苦参注射液联合放射性~(125)I粒子植入治疗原发性肝癌的临床研究[J]. 贵州医药, 2017, 41(1):39-41.
[32] ZHANG L, HU B, LI W, et al.(125)I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis:A Systematic Review[J]. Cardiovasc Intervent Radiol, 2020, 43(2):196-203.
[33] ZHANG Z-H, ZHANG W, GU J-Y, et al.Treatment of Hepatocellular Carcinoma with Tumor Thrombus with the Use of Iodine-125 Seed Strand Implantation and Transarterial Chemoembolization:A Propensity-Score Analysis[J]. Journal of Vascular and Interventional Radiology. 2018, 29(8):1085-1093.
[34] LU J, GUO JH, ZHU HD, et al.Safety and Efficacy of Irradiation Stent Placement for Malignant Portal Vein Thrombus Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience[J]. J Vasc Interv Radiol, 2017, 28(6):786-794 e783.
[35] LIU K MX, PENG J, YANG K, et al.The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma[J]. J Clin Med Res, 2016, 8(4):297-302.
[36] LENCIONI R, MARRERO J, VENOOK A, et al.Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study[J]. Int J Clin Pract, 2010, 64(8):1034-1041.
[37] KUDFO M UK, IKEDA M, TORIMURA T, et al.Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC):TACTICS trial[J]. J Clin Oncol, 2018, 35(4):206.
[38] Kudo M.A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden:Initial Lenvatinib Therapy with Subsequent Selective TACE[J]. Liver Cancer, 2019, 8(5):299-311.
[39] LU W, JIN XL, YANG C, et al.Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma:A single-center randomized controlled trial[J]. Cancer Biol Ther, 2017, 18(6):433-438.
[40] LIU J XS, Duan X, et al.Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma[J]. Cancer Chemother Pharmacol, 2020, 85(1):69-76.
[41] XIEC DA, MABRY-HRONES D, et al.Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer[J]. Hepatology, 2019, 69(5):2048-2060.
[42] DUFFY AG US, MAKOROVA-RUSHER O, et al.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepato, 2017, 66(3):545-551.
[43] WU Q, CHEN X, WANG P, et al.Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma[J]. ACS Appl Mater Interfaces, 2020, 12(7):8016-8029.
[44] BIAN Y, GUO D.Targeted Therapy for Hepatocellular Carcinoma:Co-Delivery of Sorafenib and Curcumin Using Lactosylated pHResponsive Nanoparticles[J]. Drug Des Devel Ther, 2020, 14:647-659.
[45] MA TC, TAN LF, SHAO HB, et al.Direct to Tumor:Transarterial Administration of Gold Nanoshells with Enhanced Targeting and Photothermal Therapy[J]. J Biomed Nanotechnol, 2017, 13(7):795-804.
[46] TAN L, WANG S, XU K, et al.Layered MoS2 Hollow Spheres for Highly-Efficient Photothermal Therapy of Rabbit Liver Orthotopic Transplantation Tumors[J]. Small, 2016, 12(15):2046-2055.
[47] SHI H, NIU M, TAN L, et al.A smart all-in-one theranostic platform for CT imaging guided tumor microwave thermotherapy based on IL@ZrO2 nanoparticles[J]. Chem Sci, 2015, 6(8):5016-5026.
[48] ZHU HD, GUO JH, HUANG M, et al.Irradiation stents vs.conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial[J]. J Hepato, 2018,68(5):970-977.
[49] CHEN LF, ZHONG HS, QI X, et al.Modified coreshell magnetic mesoporous zirconia nanoparticles formed through a facile "outside-to-inside" way for CT/MRI dual-modal imaging and magnetic targeting cancer chemotherapy[J]. RSC Adv, 2019, 9(23):13220-13233.
[50] WANG D, ZHANG S, ZHANG T, et al.Pullulan-coated phospholipid and Pluronic F68 complex nanoparticles for carrying IR780 and paclitaxel to treat hepatocellular carcinoma by combining photothermal therapy/photodynamic therapy and chemotherapy[J].Int J Nanomedicine, 2017, 12:8649-8670.
[51] CHEN Q, CHEN J, HE M, et al.Novel small molecular dye-loaded lipid nanoparticles with efficient near-infrared-II absorption for photoacoustic imaging and photothermal therapy of hepatocellular carcinoma[J]. Biomater Sci, 2019, 7(8):3165-3177.
[52] ZHANG D, ZHENG A, LI J, et al.Smart Cu(II)-aptamer complexes based gold nanoplatform for tumor micro-environment triggered programmable intracellular prodrug release, photodynamic treatment and aggregation induced photothermal therapy of hepatocellular carcinoma[J]. Theranostics, 2017, 7(1):164-179.